Literature DB >> 1277211

Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

J Draeger, G Peter, H J Hohorst.   

Abstract

The reaction of 4-hydroxycyclophosphamide (4-hydroxy-CP) with sulfhydryl (SH) compounds was studied, and although the cytotoxic activity was lost a significant stabilization of the alkylating capacity was observed at the same time. We were able to show that the reaction of 4-hydroxy-CP with thiols lead to an equilibrium between the reaction product and the starting substrates. On the basis of this equilibrium the increased stabilization of the alkylating capacity of the 4-hydroxy-CP derivatives by raising the SH concentration can be explained. The different degrees of stabilization depending on the structure of the thiol results from different equilibria. the effect on the toxification reaction resulting from this equilibrium, in connection with the tautomeric equilibrium between 4-hydroxy-CP and aldophosphamide, is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277211

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

2.  Desferrioxamine protects against toxic damage to liver and kidney induced by cyclophosphamide.

Authors:  Muhammad Raza; Abdullah A Alghasham
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

3.  Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.

Authors:  R H Peters; K Ballard; J E Oatis; D J Jollow; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.

Authors:  G J Sewell
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

5.  Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.

Authors:  D S Zaharko; J M Covey; G Hörpel
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

10.  Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.